PARP1 and cancer: The simultaneous inhibition of multiple complementary DDR pathways by somatic mutation in the tumor and/or one or more targeted treatments, such as the synthetic lethality between PARP1 inhibition and BRCA1 loss of function11,12, was therefore identified as a promising therapeutic strategy in clinical cancer treatments.